These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 38820707

  • 1. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
    Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A, Longo F, Gianesin B, Forni GL, Webthal® project.
    Blood Cells Mol Dis; 2024 Jul; 107():102859. PubMed ID: 38820707
    [Abstract] [Full Text] [Related]

  • 2. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.
    Cochrane Database Syst Rev; 2017 Aug 15; 8(8):CD007476. PubMed ID: 28809446
    [Abstract] [Full Text] [Related]

  • 3. Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes.
    Yusuf S, Herdata HN, Edward ED, Khairunnisa K.
    F1000Res; 2023 Aug 15; 12():154. PubMed ID: 39233713
    [Abstract] [Full Text] [Related]

  • 4. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
    Neufeld EJ.
    Blood; 2006 May 01; 107(9):3436-41. PubMed ID: 16627763
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA, Hamam MA, Taha OA, Hazaa SM.
    Infect Disord Drug Targets; 2015 May 01; 15(2):98-105. PubMed ID: 26205801
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.
    Premawardhena A, Perera C, Wijethilaka MN, Wanasinghe SK, Rajakaruna RHMG, Samarasinghe RANKK, Williams S, Mettananda S.
    BMJ Open; 2024 Feb 08; 14(2):e077342. PubMed ID: 38331857
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ.
    Cochrane Database Syst Rev; 2018 May 08; 5(5):CD012349. PubMed ID: 29737522
    [Abstract] [Full Text] [Related]

  • 9. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; 2013(8):CD004450. PubMed ID: 23963793
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A, Kattamis A, Felisi M, Reggiardo G, El-Beshlawy A, Bejaoui M, Sherief L, Christou S, Cosmi C, Della Pasqua O, Del Vecchio GC, Filosa A, Cuccia L, Hassab H, Kreka M, Origa R, Putti MC, Spino M, Telfer P, Tempesta B, Vitrano A, Tsang YC, Zaka A, Tricta F, Bonifazi D, Ceci A.
    Lancet Haematol; 2020 Jun 21; 7(6):e469-e478. PubMed ID: 32470438
    [Abstract] [Full Text] [Related]

  • 11. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Poggi M, Sorrentino F, Pugliese P, Smacchia MP, Daniele C, Equitani F, Terlizzi F, Guitarrini MR, Monti S, Maffei L, Losardo A, Pasin M, Toscano V.
    Ann Hematol; 2016 Apr 21; 95(5):757-63. PubMed ID: 26957357
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.
    Forni GL, Podestà M, Musso M, Piaggio G, Musallam KM, Balocco M, Pozzi S, Rosa A, Frassoni F.
    Haematologica; 2013 Apr 21; 98(4):555-9. PubMed ID: 23242593
    [Abstract] [Full Text] [Related]

  • 13. Effects on hearing after long-term use of iron chelators in beta-thalassemia: Over twenty years of longitudinal follow-up.
    Aldè M, Ambrosetti U, Giuditta M, Cassinerio E, Piatti G.
    Auris Nasus Larynx; 2024 Apr 21; 51(2):271-275. PubMed ID: 37903661
    [Abstract] [Full Text] [Related]

  • 14. Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
    Forni GL, Kattamis A, Kuo KHM, Maggio A, Sheth S, Taher AT, Viprakasit V.
    Pediatr Blood Cancer; 2024 Aug 21; 71(8):e31035. PubMed ID: 38753107
    [Abstract] [Full Text] [Related]

  • 15. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
    Ricchi P, Meloni A, Pistoia L, Gamberini MR, Cuccia L, Allò M, Putti MC, Spasiano A, Rosso R, Cecinati V, Righi R, Renne S, Peritore G, Vallone A, Positano V, Quaia E, Cademartiri F, Pepe A.
    Blood Transfus; 2024 Jan 21; 22(1):75-85. PubMed ID: 37146300
    [Abstract] [Full Text] [Related]

  • 16. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Jan 21; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 17. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep 21; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 18. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
    Pennell DJ, Porter JB, Piga A, Lai YR, El-Beshlawy A, Elalfy M, Yesilipek A, Kilinç Y, Habr D, Musallam KM, Shen J, Aydinok Y, CORDELIA study investigators.
    Am J Hematol; 2015 Feb 21; 90(2):91-6. PubMed ID: 25345697
    [Abstract] [Full Text] [Related]

  • 19. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep 21; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 20. No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
    Saleem A, Waqar E, Shuja SH, Naeem U, Moeed A, Rais H, Ahmed J.
    Transfus Clin Biol; 2023 Feb 21; 30(1):69-74. PubMed ID: 35878782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.